IDH1 R132H Recombinant Rabbit Monoclonal Antibody
Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. The high frequency and distribution of the IDH1 R132H mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma WHO grade II from pilocytic astrocytoma or ependymoma.
Specifications
- Catalog No.
- BX50228
- Clone No.
- BP6205
- Application
- IHC-P
- Subcellular location
- Cytoplasm
- Control
- Glioma
- Recommended method
- HIER
- Volume
- 100μl/vial, 1ml/vial
- Dilution
- 1:100-1:200
- Immunogen
- Synthetic peptide. This information is proprietary to Biolynx and/or its suppliers.
Reference
1. Reuss D et al.Acta Neuropathol. 129(1):133-146, 2015.
2. David NL et al. Acta Neuropathol. 131:803-820, 2016.
Support Documents
Order
- E-mail : sales@biolynx.cn
